vs
Side-by-side financial comparison of Celanese Corp (CE) and Organon & Co. (OGN). Click either name above to swap in a different company.
Celanese Corp is the larger business by last-quarter revenue ($2.2B vs $1.5B, roughly 1.5× Organon & Co.). Celanese Corp runs the higher net margin — 0.6% vs -13.6%, a 14.2% gap on every dollar of revenue. On growth, Organon & Co. posted the faster year-over-year revenue change (-5.3% vs -7.0%). Celanese Corp produced more free cash flow last quarter ($168.0M vs $96.0M). Over the past eight quarters, Organon & Co.'s revenue compounded faster (-3.6% CAGR vs -8.1%).
Celanese Corporation, formerly known as Hoechst Celanese, is an American technology and specialty materials company headquartered in Irving, Texas. It is a Fortune 500 corporation. The company is the world's leading producer of acetic acid, producing about 1.95 million tonnes per year, representing approximately 20% of global production. Celanese is also the world's largest producer of vinyl acetate monomer (VAM).
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
CE vs OGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.2B | $1.5B |
| Net Profit | $14.0M | $-205.0M |
| Gross Margin | 19.1% | 49.2% |
| Operating Margin | 4.0% | -9.8% |
| Net Margin | 0.6% | -13.6% |
| Revenue YoY | -7.0% | -5.3% |
| Net Profit YoY | 100.7% | -288.1% |
| EPS (diluted) | $0.13 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $2.4B | $1.6B | ||
| Q2 25 | $2.5B | $1.6B | ||
| Q1 25 | $2.4B | $1.5B | ||
| Q4 24 | $2.4B | $1.6B | ||
| Q3 24 | $2.6B | $1.6B | ||
| Q2 24 | $2.7B | $1.6B | ||
| Q1 24 | $2.6B | $1.6B |
| Q4 25 | $14.0M | $-205.0M | ||
| Q3 25 | $-1.4B | $160.0M | ||
| Q2 25 | $199.0M | $145.0M | ||
| Q1 25 | $-21.0M | $87.0M | ||
| Q4 24 | $-1.9B | $109.0M | ||
| Q3 24 | $116.0M | $359.0M | ||
| Q2 24 | $155.0M | $195.0M | ||
| Q1 24 | $121.0M | $201.0M |
| Q4 25 | 19.1% | 49.2% | ||
| Q3 25 | 21.5% | 53.5% | ||
| Q2 25 | 21.1% | 54.8% | ||
| Q1 25 | 19.9% | 55.6% | ||
| Q4 24 | 22.7% | 56.3% | ||
| Q3 24 | 23.5% | 58.3% | ||
| Q2 24 | 24.2% | 58.4% | ||
| Q1 24 | 21.2% | 59.0% |
| Q4 25 | 4.0% | -9.8% | ||
| Q3 25 | -52.7% | 15.2% | ||
| Q2 25 | 9.2% | 14.4% | ||
| Q1 25 | 7.0% | 6.7% | ||
| Q4 24 | -59.3% | 8.1% | ||
| Q3 24 | 9.4% | 13.1% | ||
| Q2 24 | 9.4% | 14.6% | ||
| Q1 24 | 8.0% | 14.5% |
| Q4 25 | 0.6% | -13.6% | ||
| Q3 25 | -56.1% | 10.0% | ||
| Q2 25 | 7.9% | 9.1% | ||
| Q1 25 | -0.9% | 5.8% | ||
| Q4 24 | -80.8% | 6.8% | ||
| Q3 24 | 4.4% | 22.7% | ||
| Q2 24 | 5.8% | 12.1% | ||
| Q1 24 | 4.6% | 12.4% |
| Q4 25 | $0.13 | $-0.78 | ||
| Q3 25 | $-12.39 | $0.61 | ||
| Q2 25 | $1.81 | $0.56 | ||
| Q1 25 | $-0.19 | $0.33 | ||
| Q4 24 | $-17.50 | $0.42 | ||
| Q3 24 | $1.06 | $1.38 | ||
| Q2 24 | $1.41 | $0.75 | ||
| Q1 24 | $1.10 | $0.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $574.0M |
| Total DebtLower is stronger | $11.4B | $8.6B |
| Stockholders' EquityBook value | $4.0B | $752.0M |
| Total Assets | $21.7B | $12.9B |
| Debt / EquityLower = less leverage | 2.81× | 11.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $574.0M | ||
| Q3 25 | — | $672.0M | ||
| Q2 25 | — | $599.0M | ||
| Q1 25 | — | $547.0M | ||
| Q4 24 | — | $675.0M | ||
| Q3 24 | — | $763.0M | ||
| Q2 24 | — | $704.0M | ||
| Q1 24 | — | $575.0M |
| Q4 25 | $11.4B | $8.6B | ||
| Q3 25 | $11.7B | $8.8B | ||
| Q2 25 | $12.7B | $8.9B | ||
| Q1 25 | $12.4B | $9.0B | ||
| Q4 24 | $11.1B | $8.9B | ||
| Q3 24 | $11.3B | $8.7B | ||
| Q2 24 | $11.1B | $8.7B | ||
| Q1 24 | $11.0B | $8.7B |
| Q4 25 | $4.0B | $752.0M | ||
| Q3 25 | $4.0B | $906.0M | ||
| Q2 25 | $5.3B | $733.0M | ||
| Q1 25 | $5.2B | $542.0M | ||
| Q4 24 | $5.2B | $472.0M | ||
| Q3 24 | $7.3B | $493.0M | ||
| Q2 24 | $7.2B | $144.0M | ||
| Q1 24 | $7.1B | $48.0M |
| Q4 25 | $21.7B | $12.9B | ||
| Q3 25 | $22.2B | $13.6B | ||
| Q2 25 | $23.7B | $13.5B | ||
| Q1 25 | $23.2B | $13.2B | ||
| Q4 24 | $22.9B | $13.1B | ||
| Q3 24 | $25.9B | $12.8B | ||
| Q2 24 | $25.8B | $12.2B | ||
| Q1 24 | $26.0B | $11.9B |
| Q4 25 | 2.81× | 11.49× | ||
| Q3 25 | 2.95× | 9.74× | ||
| Q2 25 | 2.41× | 12.14× | ||
| Q1 25 | 2.39× | 16.52× | ||
| Q4 24 | 2.14× | 18.81× | ||
| Q3 24 | 1.56× | 17.75× | ||
| Q2 24 | 1.54× | 60.11× | ||
| Q1 24 | 1.56× | 181.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $252.0M | $141.0M |
| Free Cash FlowOCF − Capex | $168.0M | $96.0M |
| FCF MarginFCF / Revenue | 7.6% | 6.4% |
| Capex IntensityCapex / Revenue | 3.8% | 3.0% |
| Cash ConversionOCF / Net Profit | 18.00× | — |
| TTM Free Cash FlowTrailing 4 quarters | $803.0M | $538.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $252.0M | $141.0M | ||
| Q3 25 | $447.0M | $264.0M | ||
| Q2 25 | $410.0M | $220.0M | ||
| Q1 25 | $37.0M | $75.0M | ||
| Q4 24 | $494.0M | $390.0M | ||
| Q3 24 | $79.0M | $141.0M | ||
| Q2 24 | $292.0M | $332.0M | ||
| Q1 24 | $101.0M | $76.0M |
| Q4 25 | $168.0M | $96.0M | ||
| Q3 25 | $383.0M | $218.0M | ||
| Q2 25 | $317.0M | $181.0M | ||
| Q1 25 | $-65.0M | $43.0M | ||
| Q4 24 | $389.0M | $335.0M | ||
| Q3 24 | $-9.0M | $99.0M | ||
| Q2 24 | $187.0M | $300.0M | ||
| Q1 24 | $-36.0M | $30.0M |
| Q4 25 | 7.6% | 6.4% | ||
| Q3 25 | 15.8% | 13.6% | ||
| Q2 25 | 12.5% | 11.4% | ||
| Q1 25 | -2.7% | 2.8% | ||
| Q4 24 | 16.4% | 21.0% | ||
| Q3 24 | -0.3% | 6.3% | ||
| Q2 24 | 7.1% | 18.7% | ||
| Q1 24 | -1.4% | 1.8% |
| Q4 25 | 3.8% | 3.0% | ||
| Q3 25 | 2.6% | 2.9% | ||
| Q2 25 | 3.7% | 2.4% | ||
| Q1 25 | 4.3% | 2.1% | ||
| Q4 24 | 4.4% | 3.5% | ||
| Q3 24 | 3.3% | 2.7% | ||
| Q2 24 | 4.0% | 2.0% | ||
| Q1 24 | 5.2% | 2.8% |
| Q4 25 | 18.00× | — | ||
| Q3 25 | — | 1.65× | ||
| Q2 25 | 2.06× | 1.52× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 3.58× | ||
| Q3 24 | 0.68× | 0.39× | ||
| Q2 24 | 1.88× | 1.70× | ||
| Q1 24 | 0.83× | 0.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CE
| Engineered Materials | $1.3B | 58% |
| Acetyl Chain | $940.0M | 43% |
OGN
Segment breakdown not available.
